PMID- 25993198
OWN - NLM
STAT- MEDLINE
DCOM- 20160208
LR  - 20211203
IS  - 1548-8756 (Electronic)
IS  - 1548-8748 (Linking)
DP  - 2015
TI  - New targeted therapies for indolent B-cell malignancies in older patients.
PG  - e365-74
LID - 10.14694/EdBook_AM.2015.35.e365 [doi]
AB  - Molecularly targeted agents have become an established component of the treatment 
      of indolent B-cell malignancies (iNHL). iNHL disproportionately affects older 
      adults, so treatments that have excellent tolerability and efficacy across 
      multiple lines of therapy are in demand. The numbers and classes of targeted 
      therapies for iNHL have proliferated rapidly in recent years; classes of agents 
      that show promise for older patients with iNHL include anti-CD20 antibodies, 
      phosphatidyl-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling 
      pathway inhibitors, immunomodulators, proteasome inhibitors, epigenetic 
      modulators, and immunotherapies. Here, we review the proposed mechanisms of 
      action, efficacy, and tolerability of novel agents for iNHL, with an emphasis on 
      their applicability to older patients.
FAU - Krem, Maxwell M
AU  - Krem MM
AD  - From the University of Louisville Brown Cancer Center, Louisville, KY; Fred 
      Hutchinson Cancer Research Center, Seattle, WA.
FAU - Gopal, Ajay K
AU  - Gopal AK
AD  - From the University of Louisville Brown Cancer Center, Louisville, KY; Fred 
      Hutchinson Cancer Research Center, Seattle, WA.
LA  - eng
GR  - K24CA184039/CA/NCI NIH HHS/United States
GR  - P01CA044991/CA/NCI NIH HHS/United States
GR  - P30 CA015704/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am Soc Clin Oncol Educ Book
JT  - American Society of Clinical Oncology educational book. American Society of 
      Clinical Oncology. Annual Meeting
JID - 101233985
RN  - 0 (Antibodies)
RN  - 0 (Antigens, CD20)
RN  - 0 (Immunoconjugates)
RN  - 0 (Immunologic Factors)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Proteasome Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase)
RN  - EC 2.7.11.1 (Oncogene Protein v-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Agammaglobulinaemia Tyrosine Kinase
MH  - Aged
MH  - Antibodies/immunology
MH  - Antigens, CD20/immunology
MH  - Forecasting
MH  - Humans
MH  - Immunoconjugates/therapeutic use
MH  - Immunologic Factors/therapeutic use
MH  - Immunotherapy/methods
MH  - Leukemia, B-Cell/*therapy
MH  - Middle Aged
MH  - Molecular Targeted Therapy/*methods
MH  - Oncogene Protein v-akt/antagonists & inhibitors
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Proteasome Inhibitors/therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Randomized Controlled Trials as Topic
MH  - Signal Transduction/immunology
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
EDAT- 2015/05/21 06:00
MHDA- 2016/02/09 06:00
CRDT- 2015/05/21 06:00
PHST- 2015/05/21 06:00 [entrez]
PHST- 2015/05/21 06:00 [pubmed]
PHST- 2016/02/09 06:00 [medline]
AID - 0011500e365 [pii]
AID - 10.14694/EdBook_AM.2015.35.e365 [doi]
PST - ppublish
SO  - Am Soc Clin Oncol Educ Book. 2015:e365-74. doi: 10.14694/EdBook_AM.2015.35.e365.